Laurence Klotz, MD, FRCSC, summarizes talks from the session he moderated on Localized Prostate Cancer, Including ADT and Radiation Oncology, during the 31st International Prostate Cancer Update in July 2021 in Snowbird, Utah. See below for links to full presentations from the conference as well as related panel discussions.
How to cite: Klotz, Laurence. “International Prostate Cancer Update 2021 Session Review: Localized Prostate Cancer, Including ADT and Radiation Oncology.” July 2021. Accessed Nov 2024. https://grandroundsinurology.com/international-prostate-cancer-update-2021-session-review-localized-prostate-cancer-including-adt-and-radiation-oncology/
Lectures from this Session:
Updates in ADT: Managing Adverse Effects – Laurence Klotz, MD, FRCSC, Professor of Surgery at the University of Toronto and the Sunnybrook Chair of Prostate Cancer Research at Sunnybrook Health Sciences Centre, reviews simple interventions physicians can use to improve quality of life and survival as well as to ameliorate unwanted side effects in prostate cancer patients undergoing androgen deprivation therapy (ADT).
Role of ADT with Radiation – Steven E. Finkelstein, MD, FACRO, radiation oncologist with Florida Cancer Affiliates in Panama City, Florida, discusses the role of androgen deprivation therapy (ADT) with radiation therapy (RT) in patients with prostate cancer.
Active Surveillance in Favorable Intermediate-Risk Prostate Cancer – James A. Eastham, MD, FACS, the Peter T. Scardino Chair in Oncology and Chief of the Urology Service in the Department of Surgery at Memorial Sloan-Kettering Cancer Center in New York, discusses the process of selecting intermediate-risk patients with prostate cancer for active surveillance (AS).
Can We Trust TRUS Biopsies? – Francisco G. La Rosa, MD, Associate Professor in the Department of Pathology at the University of Colorado Anschutz Medical Campus in Denver, evaluates the efficacy of transrectal ultrasonography (TRUS) biopsy and contrasts the technique with transperineal prostate mapping biopsy (TPMB).
Management of Biochemical Recurrence After Surgery or Radiation – Peter R. Carroll, MD, MPH, Professor of Prostate Cancer and Urology at the University of California, San Francisco, discusses advancements in knowledge of biochemical recurrence post radical prostatectomy.
Contemporary Brachytherapy: A View from the ABS – Brian J. Moran, MD, the Medical Director for the Chicago Prostate Cancer Center and the Director of Radiation Oncology at DuPage Medical Group, outlines how improved diagnostics have led to better-targeted brachytherapy treatment for localized prostate cancer.
Updates in Radiation Oncology: A View From ACRO – Steven E. Finkelstein, MD, FACRO, a radiation oncologist with Florida Cancer Affiliates in Panama City, Florida, discusses the American College of Radiation Oncology (ACRO) and their goals for leadership, education, advocacy, and recognition in their field.
ADT Panel Discussion
Raoul S. Concepcion, MD, FACS, Chief Science Officer of U.S. Urology Partners in Nolensville, Tennessee, leads a panel discussion on androgen deprivation therapy (ADT) for prostate cancer, focusing on adverse effects, agonists vs. antagonists, and overtreatment. The panel includes: David M. Albala, MD, Chief of Urology at Crouse Hospital in Syracuse, New York; Scott B. Sellinger, MD, a partner with the Advanced Urology Institute; Peter M. Knapp, MD, FACS, a urologist with Urology of Indiana, LLC; and R. Jonathan Henderson, MD, a urologist with Regional Urology, LLC, in Shreveport, Louisiana, and president of LUGPA.
How to cite: Concepcion, Raoul S. “ADT Panel Discussion.” July 2021. Accessed Nov 2024. https://grandroundsinurology.com/international-prostate-cancer-update-2021-session-review-localized-prostate-cancer-including-adt-and-radiation-oncology/
Panel Discussion: Management of High-Risk, Non-Metastatic Prostate Cancer – The Case for Surgery
James A. Eastham, MD, FACS, moderates a panel discussion focused on high-risk non-metastatic PCa. The panel features Francesco G. La Rosa, MD, Associate Professor in the Department of Pathology at the University of Colorado Anschutz Medical Campus in Denver, and Peter R. Carroll, MD, MPH, Professor of Prostate Cancer and Urology at the University of California, San Francisco.
How to cite: Eastham, James A. “Panel Discussion: Management of High-Risk, Non-Metastatic Prostate Cancer – The Case for Surgery.” July 2021. Accessed Nov 2024. https://grandroundsinurology.com/international-prostate-cancer-update-2021-session-review-localized-prostate-cancer-including-adt-and-radiation-oncology/
About The 31st Annual International Prostate Cancer Update:
The International Prostate Cancer Update (IPCU), founded in 1990, is a multi-day CME conference focused on prostate cancer treatment updates with expert, international faculty. It is led by expert physicians and is designed for urologists, medical oncologists, radiation oncologists, and other healthcare professionals involved in the diagnosis and treatment of prostate cancer. The educational activities featured here were presented during the 31st iteration of the meeting in July 2021 in Snowbird, Utah.
ABOUT THE AUTHOR
Laurence Klotz, MD, FRCSC, is a professor of surgery at the University of Toronto and the Sunnybrook Chair of Prostate Cancer Research. Dr. Klotz was the founding editor-in-chief of both the Canadian Journal of Urology and the Canadian Urology Association Journal (CUAJ), and he is now editor emeritus of the CUAJ. Dr. Klotz obtained his medical degree and completed his residency at the University of Toronto. He was also a uro-oncology fellow at Memorial Sloan Kettering Cancer Center in New York.
Dr. Klotz has 550 peer review publications and eight books. He coined the phrase “active surveillance” and successfully championed this approach for men with favorable-risk prostate cancer against substantial resistance. He was the associate editor of the Journal of Urology, responsible for prostate cancer, for eight years. Dr. Klotz received the Queen’s Jubilee Medal for outstanding public service, the University of Toronto's Lister Prize, the Society of Urologic Oncology’s SUO Medal, the American Urological Association’s Richard Williams Award, the University of Toronto's Lifetime Achievement Award, the Canadian Urological Association Lifetime Achievement Award, and the Harold Warwick Award from the Canadian Cancer Society for “outstanding contributions to cancer control.” In 2015 he was inducted as a Member of the Order of Canada, Canada’s highest civilian award.
